A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP)

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Riociguat (Primary)
  • Indications Idiopathic pulmonary fibrosis; Pulmonary hypertension
  • Focus Therapeutic Use
  • Acronyms RISE-IIP
  • Sponsors Bayer
  • Most Recent Events

    • 14 Jan 2017 This trial has been completed in Portugal (End date:2016-09-14) as per European Clinical Trials Database record.
    • 02 Oct 2016 This trial was completed in Spain.
    • 24 Sep 2016 This trial was completed in Denmark and Belgium(14 Sep 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top